BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SciLifeLab - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.scilifelab.se
X-WR-CALDESC:Events for SciLifeLab
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240212T140000
DTEND;TZID=Europe/Stockholm:20240212T153000
DTSTAMP:20260403T213127
CREATED:20240112T143939Z
LAST-MODIFIED:20240112T143942Z
UID:10001106-1707746400-1707751800@www.scilifelab.se
SUMMARY:The importance of target validation for successful academic drug discovery 
DESCRIPTION:Join us for an exciting webinar delving into the topic of target validation in academic drug discovery.  \n\n\n\nDiscover strategies for effective target validation from our experts. Register now for our joint webinar with Karolinska Institutet and SciLifeLab Drug Discovery & Development and secure your spot \n\n\n\nRead more
URL:https://www.scilifelab.se/event/the-importance-of-target-validation-for-successful-academic-drug-discovery/
CATEGORIES:Event
ATTACH;FMTTYPE=image/png:https://www.scilifelab.se/wp-content/uploads/2023/02/DDD-text-logga.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20231107T130000
DTEND;TZID=Europe/Stockholm:20231107T140000
DTSTAMP:20260403T213127
CREATED:20231030T125153Z
LAST-MODIFIED:20231030T132952Z
UID:10001009-1699362000-1699365600@www.scilifelab.se
SUMMARY:Discovery of SARS-CoV-2 Main Protease inhibitors at the DDD platform
DESCRIPTION:Pandemic preparedness and the generation of SARS-CoV-2 inhibitors – A new exit from SciLifeLab Drug Discovery and Development platform \n\n\n\nDDD Exit Event 2023-11-07\, zoomcast 13.00 \n\n\n\n \n\n\n\nPresenters\n\n\n\nDr. Ulf Ribacke. Dept. of Microbiology\, Tumor and Cell Biology\, Karolinska InstitutetTel: +46 70 497 5196\, Email: ulf.ribacke@ki.se \n\n\n\nProf. Jens Carlsson\, Dept. of Cell and Molecular Biology\, Uppsala UniversityTel: +46 72 227 7976\, Email: jens.carlsson@icm.uu.se \n\n\n\nAbstract\n\n\n\nSciLifeLab has been commissioned by the government to build laboratory capacity to assist in future pandemics through research and competence and technology development. Hear more about the SciLifeLab Pandemic Laboratory Preparedness program from Ulf Ribacke\, (SciLifeLab and Karolinska Institutet) and groundbreaking research performed by researchers at Uppsala University that led to discovery of potent main protease SARS-CoV-2 inhibitors. \n\n\n\nJens Carlsson\, Helena Danielson\, Anja Sandström and Lindon Moodie have recently signed an agreement for international partnering of a project focusing on development of drugs for treatment of COVID-19 (DP_JC_188). \n\n\n\nThe project was funded by the National COVID-19 Research Program initiated by the Knut and Alice Wallenberg Foundation. Hit compounds identified by virtual screening were published in 2022 by Luttens et al. (https://doi.org/10.1021/jacs.1c08402). Hit-to-lead generation was then performed together with the Drug Discovery and Development Platform in the DP_JC_188 project. Lead optimization and preclinical development of assets are now supported by an international pharmaceutical company. \n\n\n\nShort speakers biography:\n\n\n\nUlf Ribacke: Ulf is scientific co-director of the SciLifeLab Pandemic Laboratory Preparedness program and heads two research labs located at Karolinska Institutet and Uppsala University\, both dedicated to resolve how malaria parasites adapt to evade cellular stress with the ultimate goal to identify targets for new interventions. \n\n\n\nJens Carlsson: Jens is a Professor of Computational Biochemistry at Uppsala University\, where his group uses computational models to understand protein function at the molecular level and develops strategies for drug discovery.For more information\, visit http://www.carlssonlab.org/. \n\n\n\nUlf RibackeKarolinska InstitutetScientific Lead – Pandemic Laboratory Preparedness at SciLifeLabulf.ribacke@ki.se\n\n\n\nJens CarlssonUppsala Universityjens.carlsson@icm.uu.se
URL:https://www.scilifelab.se/event/discovery-of-sars-cov2-mpro-inhibitors-at-the-ddd-platform/
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230816T100000
DTEND;TZID=Europe/Stockholm:20230816T104500
DTSTAMP:20260403T213127
CREATED:20230621T114415Z
LAST-MODIFIED:20230815T130146Z
UID:10000919-1692180000-1692182700@www.scilifelab.se
SUMMARY:Project support in chemical biology and drug discovery
DESCRIPTION:The chemical biology unit (CBCS) and the Drug discovery and development (DDD) platform at SciLifeLab have calls out for projects. \n\n\n\nCBCS is looking for projects in Chemical Biology which includes assay development for small molecule screening and profiling\, as well as enabling chemistry. For more information\, please visit www.cbcs.se. \n\n\n\nThe DDD platform has a call looking for new project proposals for drug discovery. All therapeutic modalities that can be developed in collaboration with the DDD platform at SciLifeLab are of interest\, including small molecules\, antibodies\, oligonucleotides and new modalities. \n\n\n\nSome users and projects are at the intersection between chemical biology and drug discovery. This webinar aims to guide users to the call that best suits the needs of their project. \n\n\n\nregister here to receive link\n\n\n\nDocumentation\n\n\n\nDDD Call for Projects \n\n\n\nCBCS Large Projects Call 2023 \n\n\n\nWebinar Slides CBCS \n\n\n\nWebinar Slides DDD
URL:https://www.scilifelab.se/event/project-support-in-chemical-biology-and-drug-discovery-2/
LOCATION:Online event via Zoom
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230628T110000
DTEND;TZID=Europe/Stockholm:20230628T120000
DTSTAMP:20260403T213127
CREATED:20230616T074651Z
LAST-MODIFIED:20230616T074652Z
UID:10000917-1687950000-1687953600@www.scilifelab.se
SUMMARY:Call for new drug discovery pilot projects at SciLifeLab DDD with special emphasis on biologics and antibiotics
DESCRIPTION:The DDD platform at SciLifeLab supports academic drug discovery project with expertise and technical capabilities. We have\, for example\, platforms to develop small molecule drugs\, therapeutic antibodies\, oligonucleotide therapeutics\, proximity-inducing agents such as bispecific antibodies and PROTACs.  \n\n\n\nIn this call\, the Drug Discovery and Development Platform (DDD) at SciLifeLab is looking for new pilot project proposals for drug discovery. All therapeutic modalities outlined above are of interest. Of special interest are new project ideas for (multispecific) biologics\, and in collaboration with ENABLE2 https://www.ilk.uu.se/enable2/\, small molecule projects for discovery of new antibiotics. \n\n\n\nNote that small projects for selections in phage display libraries for antibodies\, selections in DNA encoded chemical libraries for small molecules or limited screening for antisense or siRNA molecules can be considered.  \n\n\n\nA description of new modalities in drug discovery research can be found here: https://pubs.acs.org/doi/10.1021/acsmedchemlett.9b00582 \n\n\n\nIf you have questions about the call please contact DDD by email (dddprojectproposal@scilifelab.se). This call is open for scientists with a doctoral degree at a Swedish university or higher institution. English should be used when filling out this application. You are responsible for ensuring that the application is complete. Incomplete applications will not be processed. \n\n\n\nProgram\n\n\n\n11.00 Introduction to Anubis call for DDD pilot-projects\, Per Arvidsson \n\n\n\n11.05 Oligonucleotide therapeutics through OligoNova HUB at DDD\, Pär Matsson \n\n\n\n11.30 Questions & Answers \n\n\n\n11.45 End with a video about collaboration with SciLifeLab DDD featuring Marika Nestor\, Uppsala University \n\n\n\n \n\n\n\nWelcome!\n\n\n\nRegistration\n\n\n\nMore About the call\n\n\n\nLink to Online Event
URL:https://www.scilifelab.se/event/call-for-new-drug-discovery-pilot-projects-at-scilifelab-ddd-with-special-emphasis-on-biologics-and-antibiotics/
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230320T110000
DTEND;TZID=Europe/Stockholm:20230320T170000
DTSTAMP:20260403T213127
CREATED:20230221T103002Z
LAST-MODIFIED:20230315T111656Z
UID:10000816-1679310000-1679331600@www.scilifelab.se
SUMMARY:Kinase Drug Discovery - Strategies for Success
DESCRIPTION:A half day dedicated to kinases in drug discovery organized by SciLifeLab DDD in collaboration with AstraZeneca.  \n\n\n\nKinases continue to attract much attention in drug discovery. Since the first compounds were launched in 2001 the learning curve of how to tackle different challenges has been steep. At the symposium we hope to give a broad overview where the field stands today and the different approaches one can take in drug discovery when interacting with kinases.  \n\n\n\nIn the late afternoon we will dive deeper into the details of data generation and data interpretation to learn and discuss different techniques that can be applied to increase the chance for success. \n\n\n\nThe meeting is believed to be valuable for researchers in the area of drug discovery like medicinal chemists\, structural biologists\, pharmacologists\, protein scientists\, toxicologists etc.  \n\n\n\nThis is a hybrid event. Registration for the conference on site is binding and last day for on site participation is March 14th. \n\n\n\nRead more\n\n\n\nRegister\n\n\n\n\n\n\n\nProgram
URL:https://www.scilifelab.se/event/kinase-drug-discovery-strategies-for-success/
LOCATION:Inghesalen\, Tomtebodavägen 18a\,\, Solna\, 171 65 171 65\, Sweden
CATEGORIES:Event
ATTACH;FMTTYPE=image/jpeg:https://www.scilifelab.se/wp-content/uploads/2023/02/Bild-2a-1-scaled.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230314T083000
DTEND;TZID=Europe/Stockholm:20230314T113000
DTSTAMP:20260403T213127
CREATED:20230207T121841Z
LAST-MODIFIED:20230213T154000Z
UID:10000805-1678782600-1678793400@www.scilifelab.se
SUMMARY:Electro- and Photoredox Chemistry – with a Practical touch
DESCRIPTION:At these two seminars you will hear about the two techniques of electrosynthesis and photoredoxchemistry\, used more and more today by organic chemists. We will get some background information to the techniques and examples from how it is used in Helena’s and Markus’ labs. After the seminars we hope that you better understand when the techniques are best used and that you also get practical examples on how to get started. \n\n\n\nWe hope to discuss what can be future developments in field. \n\n\n\nAt the venue we will bring examples of equipment that can be used. \n\n\n\nWe meet up in the entrance at Gamma 2 for coffee and walk up together (be there in time\, so we can let you in). To reserve a sandwich please register before March 7th to ylva.gravenfors@scilifelab.se \n\n\n\n \n\n\n\nWe look forward to seeing you there! \n\n\n\nPresenter\n\n\n\nDr Helena Lundberg\, Ass. Professor at KTH \n\n\n\nhellundb@kth.se \n\n\n\nDr Markus Kärkäs\, Assoc. Professor at KTH \n\n\n\nkarkas@kth.se \n\n\n\nSpeakers‘ biographies \n\n\n\nHelena is Assistant Professor in organic chemistry since 2021 and has been a principal investigator at KTH Royal Institute of Technology since early 2019. Helena’s research interests are centered around catalysis and reductive electrosynthesis.   \n\n\n\nMarkus is Associate Professor in organic chemistry and a principal investigator at KTH Royal Institute of Technology since August 2018. His research interests include photoredox catalysis\, organic electrosynthesis\, and artificial photosynthesis. \n\n\n\nThe Drug Discovery and Development Platform\n\n\n\nHit2Lead – Read more
URL:https://www.scilifelab.se/event/electro-and-photoredox-chemistry-with-a-practical-touch/
LOCATION:Gamma 7 Lunchroom\, Tomtebodavägen 23A\, Solna\, 17121
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230124T100000
DTEND;TZID=Europe/Stockholm:20230124T104500
DTSTAMP:20260403T213128
CREATED:20230110T160227Z
LAST-MODIFIED:20230124T132100Z
UID:10000783-1674554400-1674557100@www.scilifelab.se
SUMMARY:Project support in chemical biology and drug discovery
DESCRIPTION:The chemical biology unit (CBCS) and the Drug discovery and development (DDD) platform at SciLifeLab have calls out for projects. \n\n\n\nCBCS is looking for projects in Chemical Biology which includes assay development for small molecule screening and profiling\, as well as enabling chemistry. For more information\, please visit www.cbcs.se. \n\n\n\nThe DDD platform has a call looking for new project proposals for drug discovery. All therapeutic modalities that can be developed in collaboration with the DDD platform at SciLifeLab are of interest\, including small molecules\, antibodies\, oligonucleotides and new modalities. \n\n\n\nSome users and projects are at the intersection between chemical biology and drug discovery.This webinar aims to guide users to the call that best suits the needs of their project. \n\n\n\nDocumentation\n\n\n\nDDD Call for Projects\n\n\n\nWebinar Slides CBCS\n\n\n\nWebinar Slides PPP
URL:https://www.scilifelab.se/event/project-support-in-chemical-biology-and-drug-discovery/
LOCATION:Online event via Zoom
CATEGORIES:Event
ATTACH;FMTTYPE=image/jpeg:https://www.scilifelab.se/wp-content/uploads/2022/04/Pawel_DDD_WP.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230119T080000
DTEND;TZID=Europe/Stockholm:20230119T170000
DTSTAMP:20260403T213128
CREATED:20221209T130532Z
LAST-MODIFIED:20221213T124743Z
UID:10000746-1674115200-1674147600@www.scilifelab.se
SUMMARY:Uppsala University Pharmaceutical Profiling in Drug Discovery and Development Symposium
DESCRIPTION:Every year\, the Drug Delivery group at the Department of Pharmacy (headed by Prof. Per Artursson\, Prof. Christel Bergström and Dr. Pawel Baranczewski) organizes a one-day symposium on pharmaceutical profiling. On January 19th\, 2023\, the 12th Uppsala University Pharmaceutical Profiling in Drug Discovery and Development Symposium will be arranged.  \n\n\n\nregistration\n\n\n\nThis twelfth edition of the symposium will focus on new modalities with respect to their development and formulation to overcome biological barriers and achieve targeted therapies. Past symposia have been highly attended by faculty and students at Uppsala University and other Swedish and international universities\, as well as by researchers from the local biotech and pharma industry and from regulatory agencies.  \n\n\n\nPrevious keynote speakers included among others Prof. Langer (MIT)\, Prof. Alonso (USC CIMUS Research Institute)\, Prof. Porter (Monash University)\, Prof. Leroux (ETH Zürich) and Dr. Hochman (Merck). The symposia provide excellent opportunities for academia-industry networking and for scientific discussions on current research at our platform for drug optimization and pharmaceutical profiling as well as in the Drug Delivery research group at the Department of Pharmacy.  \n\n\n\nThis year’s confirmed speakers and the titles of their talks:  \n\n\n\n\nProf. Olivia Merkel (Ludwig-Maximilians-Universität München\, Germany): Treatment of lung diseases via siRNA inhalation delivery \n\n\n\nProf. Paola Luciani (University of Bern\, Switzerland): Targeting fibrosis in multiple organs via lipid-based drug delivery systems \n\n\n\nProf. Ola Söderberg (Uppsala University\, Sweden): Development of novel molecular biology tools for medical research \n\n\n\nAssist. Prof. Daniel Fürth (Uppsala University\, Sweden): A chemoselective in vivo sequencing chemistry \n\n\n\nProf. Yvonne Perrie (University of Strathclyde\, Scotland): Formulation strategies for the delivery of mRNA vaccines \n\n\n\nProf. My Hedhammar (KTH Royal Institute of Technology/Spiber Technologies AB\, Sweden): FN-silk membrane as mimic of basement membrane in tissue barrier models \n\n\n\nAssoc. Prof. Daniel Espes (Uppsala University\, Sweden): Novel imaging techniques and drugs for targeting human pancreatic islets \n\n\n\nProf. Per I Arvidsson (Karolinska Institutet\, Sweden): Explorations and innovations at the academia-industry interface – tales from the SciLifeLab DDD infrastructure \n\n\n\nProf. Jens Carlsson (Uppsala University\, Sweden): Antiviral drug discovery by virtual screening of ultra-large chemical libraries \n\n\n\n\nThere will also be a panel discussion about “Impact of European drug delivery science”\, led by Dr. Björn Arvidsson. \n\n\n\nOrganizers: \n\n\n\n\nDrug Delivery group\, Uppsala University\n\n\n\nSciLifeLab\n\n\n\nUDOPP
URL:https://www.scilifelab.se/event/uppsala-university-pharmaceutical-profiling-in-drug-discovery-and-development-symposium/
LOCATION:Humanities Theater\, Engelska parken\, Uppsala\, 75238\, Sweden
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230111T110000
DTEND;TZID=Europe/Stockholm:20230111T114500
DTSTAMP:20260403T213128
CREATED:20221220T095206Z
LAST-MODIFIED:20230109T155739Z
UID:10000754-1673434800-1673437500@www.scilifelab.se
SUMMARY:Call for new drug discovery pilot projects at SciLifeLab DDD with special emphasis on new modalities and antibiotics
DESCRIPTION:Program\n\n\n\n\nInformation of new DDD call in Anubis – Per Arvidsson\n\n\n\n”Antibiotic research through DDD and Enable2” – Anders Karlén\n\n\n\n”New modalities as therapies of the future” – Per Arvidsson\n\n\n\n\nIn this call\, the Drug Discovery and Development Platform (DDD) at SciLifeLab is looking for new pilot project proposals for drug discovery. All therapeutic modalities are of interest. Of special interest are new project ideas for new modalities including therapeutic oligonucleotides\, and in collaboration with ENABLE2 https://www.ilk.uu.se/enable2/\, projects for discovery of new antibiotics. \n\n\n\nNote that shorter projects for selections in phage display libraries for antibodies and in DNA encoded chemical libraries for small molecules can be considered.A description of new modalities in drug discovery research can be found here: https://pubs.acs.org/doi/10.1021/acsmedchemlett.9b00582 \n\n\n\nProgram\n\n\n\n11.00 Introduction to Anubis call for DDD pilot-projects\, Kristian Sandberg \n\n\n\n11.05 Antibiotic drug discovery through ENABLE2 and DDD\, Anders Karlén \n\n\n\n11.15 Oligonucleotide therapeutics through OligoNova HUB at DDD\, Pär Matsson \n\n\n\n11.25 New therapeutic modalities and selection in enormous antibody and small molecule libraries\, Per Arvidsson \n\n\n\n11.40 Questions & Answers\, Moderated by Kristian Sandberg \n\n\n\nIf you have questions about the call please contact DDD by email (dddprojectproposal@scilifelab.se). This call is open for scientists with a doctoral degree at a Swedish university or higher institution. English should be used when filling out this application. You are responsible for ensuring that the application is complete. Incomplete applications will not be processed. \n\n\n\nMore about the call\n\n\n\nRegistration to the Event
URL:https://www.scilifelab.se/event/call-for-new-drug-discovery-pilot-projects-at-scilifelab-ddd-with-special-emphasis-on-new-modalities-and-antibiotics/
LOCATION:Online event via Zoom
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220815T113000
DTEND;TZID=Europe/Stockholm:20220815T121500
DTSTAMP:20260403T213128
CREATED:20220615T132143Z
LAST-MODIFIED:20220622T114102Z
UID:10000625-1660563000-1660565700@www.scilifelab.se
SUMMARY:Calls for new project support in chemical biology and drug discovery
DESCRIPTION:The chemical biology unit (CBCS) and the Drug discovery and development (DDD) platform at SciLifeLab have calls out for projects. \n\n\n\nCBCS is looking for projects in Chemical Biology which includes assay development for small molecule screening and profiling\, as well as enabling chemistry. For more information\, please visit www.cbcs.se. \n\n\n\nThe DDD platform has a call looking for new project proposals for drug discovery. All therapeutic modalities that can be developed in collaboration with the DDD platform at SciLifeLab are of interest\, including small molecules\, antibodies\, oligonucleotides and new modalities. \n\n\n\nSome users and projects are at the intersection between chemical biology and drug discovery.This webinar aims to guide users to the call that best suits the needs of their project. \n\n\n\nRegistration
URL:https://www.scilifelab.se/event/calls-for-new-project-support-in-chemical-biology-and-drug-discovery/
LOCATION:Online event via Zoom
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220617T113000
DTEND;TZID=Europe/Stockholm:20220617T121500
DTSTAMP:20260403T213128
CREATED:20220608T073241Z
LAST-MODIFIED:20220608T114734Z
UID:10000623-1655465400-1655468100@www.scilifelab.se
SUMMARY:Call for new drug discovery projects - New SciLifeLab Capability for DNA encoded chemical libraries
DESCRIPTION:Call for new drug discovery projects to SciLifeLab DDD for the fall 2022 and introduction of a SciLifeLab capability for DNA encoded chemical libraries \n\n\n\nThe Drug Discovery and Development platform at SciLifeLab (DDD) opens for new project applications for the fall 2022. New proposals will be accepted for all therapeutic modalities that are currently part of the DDD offer\, i.e. small molecules\, biologics (antibodies\, proteins\, etc)\, or therapeutic oligonucleotides.  \n\n\n\nIn this presentation\, we will zoom in on selection of small molecule protein binders from enormously large DNA encoded chemical libraries containing >5 Billion physical small molecules. \n\n\n\nMost welcome! \n\n\n\nRegister to receive zoom link\n\n\n\nCall application form
URL:https://www.scilifelab.se/event/call-for-new-drug-discovery-projects-new-scilifelab-capability-for-dna-encoded-chemical-libraries/
LOCATION:Online event via Zoom
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220525T130000
DTEND;TZID=Europe/Stockholm:20220525T140000
DTSTAMP:20260403T213128
CREATED:20220507T134201Z
LAST-MODIFIED:20220510T114934Z
UID:10000603-1653483600-1653487200@www.scilifelab.se
SUMMARY:A novel\, antibody-based radiopharmaceutical for advanced thyroid cancer
DESCRIPTION:Presenter: Dr Marika Nestor\, Department of Immunology\, genetics and pathology\, Uppsala University\, Sweden \n\n\n\nMolecular radiotherapy is increasingly becoming a powerhouse in the field of cancer- and radiation therapy. By targeting a structure that is abundant on tumor cells but scarce in healthy tissues\, a cancer-targeting molecule labeled with a therapeutic radionuclide can mediate the delivery of radioactivity specifically to cancer cells. This creates a targeted\, localized form of radiotherapy that combines the advantages of systemic therapy with therapeutically effective radiation. \n\n\n\nIn a collaboration with the Drug Discovery & Development platform at Science for Life Laboratory\, we have developed an antibody-based radiopharmaceutical for molecular radiotherapy of advanced thyroid carcinoma. The project spans over the whole early development chain; from preclinical innovation in the lab\, dosimetry and proof-of-concept in animal models\, to upscaled production and preparations for first-in-man studies. \n\n\n\nDr Nestor in her presentation will discuss the process from innovation to implementation of the project\, both from a research and a commercialization perspective. \n\n\n\nsign up here\n\n\n\nMarika Nestor leads a translational research group at the Department of Immunology\, Genetics and Pathology\, Uppsala University. Her research group focuses on radionuclide targeting and radiosensitization of cancer cells. She obtained her PhD at Uppsala University in 2006\, and became an Associate Professor in 2012. In 2013 she was awarded the Göran Gustafsson prize for young scientists\, in 2016 the Junior Investigator Award from the Swedish Cancer Society\, and in 2020 the Senior Investigator Award. In 2019\, she was awarded a grant from Sweden’s innovation agency VINNOVA to facilitate clinical translation of her findings\, as well as an Attractive Innovation Award by UU Innovation.
URL:https://www.scilifelab.se/event/a-novel-antibody-based-radiopharmaceutical-for-advanced-thyroid-cancer/
LOCATION:Online event via Zoom
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220426T093000
DTEND;TZID=Europe/Stockholm:20220426T120000
DTSTAMP:20260403T213128
CREATED:20220411T114853Z
LAST-MODIFIED:20220411T115121Z
UID:10000581-1650965400-1650974400@www.scilifelab.se
SUMMARY:New developments in upstream bioprocessing technologies seminar
DESCRIPTION:Presentation och demonstration av nya single use bioreactors (SUB) för mammalieceller.  \n\n\n\nregister to attend\n\n\n\nProgram:  \n\n\n\n9:30-10:15 Matthijs Neimeijer\, Cultivating red blood cells in singe-use bioreactors \n\n\n\n10:15-10:45 Fika och demonstration \n\n\n\n10:45-11:30 Michel Kensler\, Comparisons in scale up and down scale \n\n\n\n11:30-12:00 Questions
URL:https://www.scilifelab.se/event/new-developments-in-upstream-bioprocessing-technologies-seminar/
LOCATION:Air&Fire\, SciLifeLab Stockholm\, Tomtebodavägen 23A\, Solna\, Sweden
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220404T140000
DTEND;TZID=Europe/Stockholm:20220404T150000
DTSTAMP:20260403T213128
CREATED:20220325T125600Z
LAST-MODIFIED:20220325T143719Z
UID:10000569-1649080800-1649084400@www.scilifelab.se
SUMMARY:Information Meeting: Call for therapeutic oligonucleotide projects
DESCRIPTION:This digital information meeting will be held April 4\, 2022 at 14.00–15.00. At this meeting\, there will be a presentation of the call and you as an applicant will have the opportunity to ask questions about the call and the application process. \n\n\n\nregister here to receive zoom link\n\n\n\nApply in the call here\n\n\n\nThe mission of the Drug Discovery and Development Platform at SciLifeLab is to support researchers in developing new drugs\, transforming academic ideas into new treatments. To this end\, the DDD platform provides state-of-the-art drug discovery technologies to scientists across the country. Therapeutic oligonucleotides are a recent addition to the DDD platform’s capacity\, complementing the previous focus on small molecule and protein drugs. Oligonucleotide drugs have different modes of action\, and a potentially faster development compared to other drug types. Therapeutic oligonucleotide development is supported by the OligoNova Hub\, based in Gothenburg and part of SciLifeLab’s DDD platform. \n\n\n\nIn this call\, we are looking for project ideas for new therapeutic oligonucleotides that can be developed at DDD and OligoNova Hub. Approved project ideas will be developed in close collaboration between the academic laboratory and drug development experts at DDD and OligoNova Hub. The costs of the projects will mainly be covered by OligoNova\, but academic partners will be expected to contribute by paying for reagent costs. \n\n\n\nThe call is open for scientists with a doctoral degree at a Swedish university or higher institution. English should be used when filling out this application. You are responsible for ensuring that the application is complete. Incomplete applications will not be processed. Attach only material that we explicitly request. SciLifeLab DDD/OligoNova will not accept additional information after the closing date for applications\, except for information we ourselves explicitly request. Applications are reviewed by a review committee with international representation. \n\n\n\nCall Announcement FlyerDownload\n\n\n\nThe call is open March 28\, 2022 to May 13\, 2022.
URL:https://www.scilifelab.se/event/information-meeting-call-for-therapeutic-oligonucleotide-projects/
LOCATION:Online event via Zoom
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220127T084500
DTEND;TZID=Europe/Stockholm:20220127T170000
DTSTAMP:20260403T213128
CREATED:20211130T143050Z
LAST-MODIFIED:20211130T160953Z
UID:10000492-1643273100-1643302800@www.scilifelab.se
SUMMARY:11th Symposium on Pharmaceutical Profiling in Drug Discovery and Development
DESCRIPTION:Uppsala University’s Department of Pharmacy hosts the 11th Pharmaceutical Profiling meeting on Thursday\, January 27\, 2022\, at The Humanities Theatre\, English Park Campus\, Uppsala. \n\n\n\nJanuary 27\, 2022The Humanities Theatre\, English Park Campus\, UppsalaConfirmed speakers \n\n\n\nKathryn A. Whitehead (Carnegie Mellon University\, US)Ola Engkvist (AstraZeneca\, Sweden)Carolina Wählby (Uppsala University\, Sweden)Samir EL Andaloussi (Karolinska Institutet\, Sweden)Ola Spjuth (Uppsala University\, Sweden)Pär Matsson (University of Gothenburg\, Sweden)Annabelle Biscans (AstraZeneca\, Sweden)\n\n\n\nWe highly encourage all participants to bring a scientific poster.
URL:https://www.scilifelab.se/event/11th-symposium-on-pharmaceutical-profiling-in-drug-discovery-and-development/
LOCATION:Humanities Theater\, Engelska parken\, Uppsala\, 75238\, Sweden
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20211208T140000
DTEND;TZID=Europe/Stockholm:20211208T150000
DTSTAMP:20260403T213128
CREATED:20211124T131507Z
LAST-MODIFIED:20211206T105940Z
UID:10000491-1638972000-1638975600@www.scilifelab.se
SUMMARY:SciLifeLab Drug Discovery Seminar & DDD Exit event: Thomas Helleday
DESCRIPTION:Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress\n\n\n\n\n\n\n\nProfessor Thomas Helleday\, Karolinska Institutet \n\n\n\nSciLifeLab Drug Discovery Seminars\, hosted by the DDD platform\, is a series of educational lectures about recent developments\, technologies\, and trends in drug discovery and development that aims to enlighten\, and spark a discussion\, within the Swedish drug discovery community. \n\n\n\nAbstract \n\n\n\nThe folate metabolism enzyme MTHFD2 is consistently overexpressed in cancer but its roles are not fully characterized and current candidate inhibitors have limited potency for clinical development. Here we demonstrate a role for MTHFD2 in DNA replication and genomic stability in cancer cells\, and present optimised potent and selective nanomolar MTHFD2 inhibitors (MTHFD2i); protein co-crystal structures demonstrated binding to the active site of MTHFD2 and target engagement and that works in vitro and in vivo. \n\n\n\nThe results demonstrate a functional link between MTHFD2-dependent cancer metabolism and replication stress that can be exploited therapeutically with this new class of inhibitors. The work\, done in collaboration with the SciLifeLab DDD platform\, is accepted in the journal Nature Cancer and is the base for the creation of a new company: One-carbon therapeutics AB.  \n\n\n\nregistration
URL:https://www.scilifelab.se/event/scilifelab-drug-discovery-seminar-ddd-exit-event/
LOCATION:Air&Fire\, SciLifeLab Stockholm\, Tomtebodavägen 23A\, Solna\, Sweden
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20211112T140000
DTEND;TZID=Europe/Stockholm:20211112T150000
DTSTAMP:20260403T213128
CREATED:20211014T151650Z
LAST-MODIFIED:20211020T131013Z
UID:10000467-1636725600-1636729200@www.scilifelab.se
SUMMARY:[Drug Discovery Seminar] PROTAC Degraders: From Fundamental Chemical Biology to Translation and Entrepreneurship
DESCRIPTION:SciLifeLab Drug Discovery Seminars\, hosted by the DDD platform\, is a series of educational lectures about recent developments\, technologies\, and trends in drug discovery and development that aims to enlighten\, and spark a discussion\, within the Swedish drug discovery community. \n\n\n\nAlessio Ciulli\n\n\n\nProfessor of Chemical Structural Biology \n\n\n\nCentre for Targeted Protein Degradation\, School of Life Sciences\, Division of Biological Chemistry and Drug Discovery\, University of Dundee \n\n\n\n \n\n\n\nAbstract\n\n\n\nProteolysis-targeting chimeras (PROTACs) are a new class of chemical tools and drugs that target disease-causing proteins for degradation. They are designed to harness the cell’s natural disposal system (the ubiquitin-proteasome) to specifically remove proteins. A PROTAC is a two-headed (i.e. bifunctional) molecule where one end binds an enzyme (an E3 ubiquitin ligase) and the other binds the target protein\, bringing the two proteins into close proximity as a ternary complex. The ligase is then able to label the target protein for ubiquitination and so degradation by the cell’s disposal system. Whereas conventional drugs only inhibit disease proteins by binding and locking up their most important functional parts for the duration of the drug’s action\, PROTACs can bind at any positions and rapidly cause the disease protein’s permanent and long-lasting destruction. Due to this revolutionary mode of action\, PROTACs can attack targets previously thought ‘undruggable’.  \n\n\n\nIn my lecture\, I will outline some key discoveries from my laboratory that have advanced the chemical structural biology of PROTACs\, and are providing fundamental insights into our understanding of their molecular recognition\, mechanism of action and drug design. I will also offer insights from our efforts to translate this fundamental science into molecular therapeutics to benefit patients\, via both partnerships with big pharma and formation of company spin-outs. Finally I will highlight the vision and mission of our recently announced new Centre for Targeted Protein Degradation at Dundee. \n\n\n\nShort Bio\n\n\n\n\n\n\n\nAlessio Ciulli holds the Personal Chair of Chemical Structural Biology at the School of Life Sciences\, University of Dundee. He is also the Director of the newly announced Dundee’s Centre for Targeted Protein Degradation (CeTPD). Dr Ciulli’s laboratory has made important contributions to selective chemical intervention on protein-protein interactions targets and to the development of proteolysis-targeting chimeric molecules (PROTACs) as a viable strategy for targeted protein degradation. Amongst his most significant discoveries are the fragment-based design of ligands for the E3 ligase von Hippel-Lindau (VHL)\, and their use to design one of the first VHL-based PROTACs: the BET degrader MZ1. Dr Ciulli’s Lab later illuminated fundamental insights into PROTACs’ mechanism of action\, solving the first crystal structure of a PROTAC ternary complex. Dr. Ciulli is the scientific founder of Amphista therapeutics\, a company that develops new protein degradation platforms. Before joining Dundee\, Dr Ciulli was a group leader at the University of Cambridge\, where he previously earned his PhD degree. Amongst his honours are the EFMC Prize for Young Medicinal Chemist in Academia\, the RSC Capps Green Zomaya Award in medicinal computational chemistry\, and election as Fellow of the Royal Society of Chemistry. \n\n\n\n \n\n\n\nRegistration
URL:https://www.scilifelab.se/event/drug-discovery-seminar-protac-degraders-from-fundamental-chemical-biology-to-translation-and-entrepreneurship/
LOCATION:Navet\, SciLifeLab Uppsala\, SciLifeLab Uppsala\, BMC C11\, Husargatan 3\, Uppsala\, 75237\, Sweden
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20211110T140000
DTEND;TZID=Europe/Stockholm:20211110T150000
DTSTAMP:20260403T213128
CREATED:20211014T151000Z
LAST-MODIFIED:20211020T130718Z
UID:10000466-1636552800-1636556400@www.scilifelab.se
SUMMARY:[Drug Discovery Seminar] How protein degradation led to faculty entrepreneurship at Yale: A personal Perspective
DESCRIPTION:SciLifeLab Drug Discovery Seminars\, hosted by the DDD platform\, is a series of educational lectures about recent developments\, technologies\, and trends in drug discovery and development that aims to enlighten\, and spark a discussion\, within the Swedish drug discovery community. \n\n\n\nCraig Crews\n\n\n\n\n\n\n\n \n\n\n\nJohn C. Malone Professor of Molecular\, Cellular\, and Developmental Biology and Professor of Chemistry\, of Pharmacology\, and of Management; Executive Dirictor\, Yale Center for Molecular Discovery\, Yale University \n\n\n\nAbstract \n\n\n\nProf. Crews is the 2021 recipient of the Scheele prize from the Swedish Pharmaceutical Society for his seminal work on protein degradation. In this talk Prof. Crews will discuss his efforts to translate research from his lab into new biopharma ventures.  To date\, these entrepreneurial  efforts have resulted in a FDA approved drug (Kyprolis) and a new therapeutic modality (PROTACs).  While each of his four companies has been launched based on different science\, they have all followed a similar business model and Prof. Crews will discuss efforts at Yale to ’systematize’ faculty entrepreneurism via a core ‘biotech accelerator’ facility. \n\n\n\nregistration\n\n\n\nBiography \n\n\n\nCrews is the John C. Malone Professor of Molecular\, Cellular and Developmental Biology and holds joint appointments in the departments of Chemistry and Pharmacology at Yale University. He graduated from the U.Virginia with a B.A. in Chemistry and received his Ph.D. from Harvard University in Biochemistry. Dr. Crews has a foothold in both the academic and biotech arenas; on the faculty at Yale since 1995\, his laboratory has pioneered the use of small molecules to control intracellular protein levels.  \n\n\n\nIn 2003\, he co-founded Proteolix\, Inc.\, whose proteasome inhibitor\, Kyprolis™ received FDA approval for the treatment of multiple myeloma. Since Proteolix’s purchase by Onyx Pharmaceuticals in 2009\, Dr. Crews has focused on a new drug development technology\, which served as the founding intellectual property for his latest New Haven-based biotech venture\, Arvinas\, Inc.  \n\n\n\nCurrently\, Dr. Crews serves on several editorial boards and was Editor of Cell Chemical Biology (2008-2018). In addition\, he has received numerous awards and honors\, including the 2013 CURE Entrepreneur of the Year Award\, 2014 Ehrlich Award for Medicinal Chemistry\, 2015 Yale Cancer Center Translational Research Prize\, a NIH R35 Outstanding Investigator Award (2015)\, the AACR Award for Chemistry in Cancer Research (2017)\, Khorana Prize from the Royal Society of Chemistry (2018)\, Pierre Fabre Award for Therapeutic Innovation (2018)\, the Pharmacia-ASPET Award for Experimental Therapeutics (2019)\, the Heinrich Wieland Prize (2020) and the Scheele Prize (2021). In 2019\, he was named an American Cancer Society Professor.
URL:https://www.scilifelab.se/event/drug-discovery-seminar-faculty-entrepreneurship-at-yale-a-personal-perspective/
LOCATION:Air&Fire\, SciLifeLab Stockholm\, Tomtebodavägen 23A\, Solna\, Sweden
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20211028T130000
DTEND;TZID=Europe/Stockholm:20211028T140000
DTSTAMP:20260403T213128
CREATED:20210930T150158Z
LAST-MODIFIED:20211014T151926Z
UID:10000459-1635426000-1635429600@www.scilifelab.se
SUMMARY:[Drug Discovery Seminars] Targeting the oncogenic TGFβ signaling pathway in cancer to inhibit invasion and metastasis
DESCRIPTION:Maréne Landström \n\n\n\nOctober 28\, 13:00-14:00 \n\n\n\n \n\n\n\nregistration\n\n\n\nWelcome to join this Drug Discovery Seminar hosted by the Drug Discovery and Development Platform. \n\n\n\nPresenter: \n\n\n\nProfessor Maréne Landström\, M.D.\, PhD \n\n\n\nDept. Medical Biosciences\, Umeå University \n\n\n\nMaréne Landström is a professor in Pathology at Department of Medical Biosciences\, Umeå University\, Sweden. She has made her postdoctoral training at the Ludwig Institute of Cancer Research\, Uppsala Branch and have also been a group leader at Department of Immunology\, Genetics and Pathology\, Uppsala University before taking on her current position. \n\n\n\nAbstract: \n\n\n\nTransforming growth factor beta (TGFb) is frequently overexpressed in several forms of cancer including prostate cancer and this has been shown to correlate with poor prognosis. TGFb is transducing its canonical and non-canonical signals via its transmembrane TGFb Type II and Type I receptors (TbRII/TbRI) which are serine-threonine kinases. We have found that the TbRI undergoes proteolytic cleavage in cancer cells in a manner dependent on the ubiquitin-ligase tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6). The intracellular domain of TbRI (TbRI-ICD) is released from the cell membrane\, soluble and is transported to the nucleus in some specific forms of cancer to promote expression of genes causing invasion and metastatic growth. In collaboration with SciLifeLab DDD we have generated potential therapeutic antibodies to target this pathway which we are investigating the function of\, in our established preclinical models for prostate cancer.
URL:https://www.scilifelab.se/event/drug-discovery-seminars-targeting-the-oncogenic-tgf%ce%b2-signaling-pathway-in-cancer-to-inhibit-invasion-and-metastasis/
LOCATION:Online event via Zoom
CATEGORIES:Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20210608T140000
DTEND;TZID=Europe/Stockholm:20210609T120000
DTSTAMP:20260403T213128
CREATED:20210503T135818Z
LAST-MODIFIED:20210607T152505Z
UID:10000373-1623160800-1623240000@www.scilifelab.se
SUMMARY:CryoEM in Drug Discovery
DESCRIPTION:CryoEM has quickly become an essential tool in academic research\, with more than 1200 cryoEM structures deposited in the PDB in 2019. CryoEM is now also showing a significant impact on drug discovery in industry and academia. \n\n\n\nThis symposium\, co-arranged by the Drug Discovery and Development platform and the CryoEM unit at SciLifeLab\, highlights some of the recent advances in the field and familiarises the audience with the requirements\, opportunities\, and limitations of the technique. Speakers include leading scientists from both major pharma companies and academia. \n\n\n\nBy attending this symposium\, you learn what cryoEM can bring to your research\, what resources are available to Swedish researchers\, and how to get started. We welcome both Swedish and international participants.  \n\n\n\n \n\n\n\n \n\n\n\n\nregister here to receive zoom link\n\n\n\n\n\n\n\nSession 1\n\n\n\nAll time slots below are in UTC+2 / CEST Time zone [Stockholm\, Sweden]. \n\n\n\nJune 8th – Afternoon\n\n\n\n14:00Welcome wordsAnnika Jenmalm-Jensen\, Infrastructure Director\, SciLifeLab14:05Introduction to the cryo-EM Unit at SciLifelabMarta Carroni\, SciLifeLab/Stockholm University\, Sweden14:15From Concept to Reality: CryoEM as an Integral Part of Drug Discovery and Development Corey Strickland; Merck\, Kenilworth\, United States14:55CryoEM at AstraZenecaChris Phillips; Astra Zeneca\, UK15:25Short break15:30An integrated cryo-EM and AI based approach for new vaccine identificationIlaria Ferlenghi\, GSK\, UK16:00Cryo-EM structure of Helicobacter pylori urease with an inhibitor in the active site at 1.68 Å resolution Hartmut Luecke\, University of Oslo\, Norway16:30CryoEM in industry\, with an artisanal touchAlexis Rohou\, Genentech\, United States17:00Wrap upMarta Carroni\, SciLifeLab/Stockholm University\, Sweden\n\n\n\nSession 2\n\n\n\nAll time slots below are in UTC+2 / CEST Time zone [Stockholm\, Sweden]. \n\n\n\nJune 9th – Morning\n\n\n\n09:00Session 2 WelcomeMarta Carroni\, SciLifeLab/Stockholm University\, Sweden09:00Cryo-EM and crystal structure of the emerging cancer target PAICS incomplex with a low-nanomolar inhibitorJana Skerlova\, Stockholm University\, Sweden09:15Using Cryo-EM for GPCR Drug Discovery and Development Patrick M. Sexton\, Monash University\, Parkville\, Australia09:55Short break10:00Cryo-EM at NovartisMaryam Khoshouei\, Novartis\, Switzerland10:30CryoEM of SARM1 reveals a trigger of axon degenerationKatie Cunnea\, Evotec\, UK11:00Concluding RemarksMarta Carroni\, SciLifeLab/Stockholm University\, SwedenPer Arvidsson\, SciLifeLab/Karolinska Institutet\, SwedenAnders Olsson\, SciLifeLab/KTH Royal Institute of Technology\, Sweden\n\n\n\n\n\n\n\nScientific committee\n\n\n\nMarta Carroni\, Head of Cryo-EM unit\, SciLifeLabPer Arvidsson\, Director Drug Discovery and Development platform\, SciLifeLabAnders Olsson\, Head of Protein Expression and Characterization unit\, SciLifeLab
URL:https://www.scilifelab.se/event/cryoem-in-drug-discovery/
CATEGORIES:Event
LOCATION:https://www.scilifelab.se/event/cryoem-in-drug-discovery/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20210604T130000
DTEND;TZID=Europe/Stockholm:20210604T134500
DTSTAMP:20260403T213128
CREATED:20210518T091847Z
LAST-MODIFIED:20210520T115320Z
UID:10000387-1622811600-1622814300@www.scilifelab.se
SUMMARY:Drug Discovery Seminars: An adaptable Drug Affinity Conjugate (ADAC) targeting CD40
DESCRIPTION:Proof of Concept and Pharmaceutical profiling\n\n\n\nSara Mangsbo\, Uppsala University\n\n\n\nAbstract: \n\n\n\nMuch attention has focused on developing CD40 directed agonistic monoclonal antibody therapy. Monoclonal antibodies targeting CD40 have been profiled for their epitope specificity and isotype in relation to their agonistic potential. Still\, clinical impact relies on a well-balanced clinical efficacy versus target-mediated toxicity. As CD40-mediated immune activation must rely on a combination of stimulation of antigen-presenting cells alongside antigen-presentation\, for efficient T cell priming\, alternative approaches to improve the therapeutic outcome of CD40-targeting strategies should focus on providing optimal antigen presentation together with CD40 stimulation. We have developed a bispecific antibody targeting CD40 as a means to carry in cargo (herein synthetic peptides) into antigen-presenting cells through a non-covalent\, high-affinity interaction between the antibody and the cargo peptide\, further referred to as the Antibody Drug Affinity Conjugate (ADAC) technology. The ADAC can improve both CD4+ and CD8+ T cell expansion in vitro and significantly improve CD8+ T cell proliferation in vivo. In addition\, the strategy leads to a stabilization of the half-life of the synthetic peptide. Future applications of ADAC involve pandemic preparedness to viral genetic drift as well as neoepitope vaccination strategies where the bispecific antibody is an off-the-shelve product\, and the peptide antigen is synthesized based on next-generation sequencing data mining.  \n\n\n\nA short speaker biography: \n\n\n\nSara Mangsbo (PhD) is Associate senior lecturer in antibody drugs and Associate professor in Experimental clinical immunology at Uppsala University. Dr Mangsbo earned her PhD in 2010 in cancer immunotherapy at Uppsala University and has since then focused her research on antibody-based drug delivery and synthetic long peptides and was recently awarded the SITC team award within the SLP stream. She is a serial entrepreneur and has founded Immuneed AB\, a service provider of immunotoxicity measurements in human whole blood. She is the Chief Development Officer of Ultimovacs and the co-founder of Vivologica AB and STRIKE pharma AB.  She drives a translational research project with the ambition and track-record of taking research projects into clinical trial testing.   \n\n\n\nRegistration
URL:https://www.scilifelab.se/event/an-adaptable-drug-affinity-conjugate-adac-targeting-cd40-proof-of-concept-and-pharmaceutical-profiling/
CATEGORIES:Event
ATTACH;FMTTYPE=image/jpeg:https://www.scilifelab.se/wp-content/uploads/2020/02/pills_600x200px.jpg
LOCATION:https://www.scilifelab.se/event/an-adaptable-drug-affinity-conjugate-adac-targeting-cd40-proof-of-concept-and-pharmaceutical-profiling/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20210526T150000
DTEND;TZID=Europe/Stockholm:20210526T160000
DTSTAMP:20260403T213128
CREATED:20210428T095007Z
LAST-MODIFIED:20210602T140817Z
UID:10000370-1622041200-1622044800@www.scilifelab.se
SUMMARY:Role of physiologically-based pharmacokinetics in regulatory submissions
DESCRIPTION:Fabienne Gaugaz Slides from the webinarDownload\n\n\n\nLuzon et al\, 2017Download\n\n\n\nAbstractPhysiologically based pharmacokinetic (PBPK) is an approach that help predict the absorption\, distribution\, metabolism and excretion (ADME) properties of candidate drugs in animal/human and evaluate the effects of intrinsic (e.g. organ dysfunction\, age\, genetics) and extrinsic (e.g. diet\, smoking habit\, drug-drug interactions) factors\, alone or in combinations\, on drug exposure\, during drug discovery and development process. Currently\, different software (i.e. SimCYP\, PK-Sim\, GastroPlus etc) are available to perform the PBPK simulations\, and the simulations are often part of regulatory submissions of small molecules and biologic new drug candidates (CD). \n\n\n\nIf successful\, the simulations may complement or replace the experimental study and/or help to explain different findings\, scenarios related to estimation of exposure and effect of new CDs. Therefore\, the regulatory authorities i.e. EMA and FDA provided guidelines\, which described how to report PBPK models and simulations in a regulatory context.Dr Gaugaz in her presentation will discuss role of PBPK simulations from small molecules and biologic CDs in submissions\, from regulatory point of view. \n\n\n\nPresenterDr Fabienne GaugazPharmacokinetics Assessor\,Medical Products Agency (Läkemedelsverket)Dag Hammarskjölds Väg 42\,752 37 Uppsala \n\n\n\nBiographyDr Fabienne Gaugaz is pharmacokinetics assessor at the Swedish Medical Product Agency (Läkemedelsverket)\, which entails the evaluation of the pharmacologically-based pharmacokinetics (PBPK) simulations related to small molecules and biologic drug candidates. Dr Gaugaz previously worked at Bayer (Wuppertal\, Germany) as lab head of research pharmacokinetics. Fabienne made her postdoc project at Karolinska Institutet (KI) and Uppsala University (UU). Dr Gaugaz obtained her Ph.D. in 2013 in pharmaceutical biology at the Institute of Pharmaceutical Sciences\, Swiss Federal Institute of Technology (ETH) in Zürich\, Switzerland and her M.Sc. in Pharmacy\, ETH\, Zürich\, Switzerland.
URL:https://www.scilifelab.se/event/role-of-physiologically-based-pharmacokinetics-in-regulatory-submissions/
CATEGORIES:Event
LOCATION:
END:VEVENT
END:VCALENDAR